Skip to main content

Day: June 7, 2023

Atlas Expands Regional Footprint with Opening of New Denver Hub

DENVER, June 07, 2023 (GLOBE NEWSWIRE) — Atlas Technical Consultants Inc. (Atlas), a leading infrastructure and environmental solutions provider, has expanded its footprint with the opening of a new hub office in Denver, Colorado. The new hub will serve as the growth and service provider for the Mountain Region. “Denver’s long-range plan for the region includes complete neighborhoods and complete transportation networks; a measured, common-sense approach to new growth; and land-use decisions through the lens of social equity,” Atlas Chief Operating Officer Ken Burns said. “This aligns with Atlas overarching goals to build sustainable and resilient communities and to offer bold, smart, innovative solutions and by staying flexible and close to our clients in economically vibrant regions like the Rocky Mountain area.” All four of...

Continue reading

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. PT. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in...

Continue reading

POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023

Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that it will host a virtual Investor Day on Tuesday, June 20, 2023, at 12:00 PM ET. The webcast is expected to last approximately 90 minutes. The event will include presentations by the Executive team on:POINT’s vertically integrated and highly differentiated platform for the development and commercialization of radiopharmaceuticals, highlighting the Company’s foundational investments into supply chain and manufacturing The significance and breadth of the untapped potential for radioligand therapy today and the...

Continue reading

Angus Gold Intersects More High-Grade Intervals of up to 5.1 g/t Au Over 8.0 Metres at the Dorset Gold Zone, Golden Sky Project

Figure 1 Surface Map – Dorset Gold Trend new drilling, Golden Sky Project Location MapHighlights:Winter 2023 infill drilling program at the Dorset Zone intersected significant gold mineralization including 5.1 g/t Au over 8.0 metres within a broader zone of 2.8 g/t Au over 16.0 metres and 3.4 g/t Au over 6.0 metres within a wider interval of 2.2 g/t Au over 16.0 metres Nine (9) of the final fifteen (15) winter drill holes were completed as infill holes on the Dorset Zone resource area and all holes intersected gold mineralization The 2023 Summer drilling program focused on the Banded Iron Formation is scheduled to begin on June 8th and will test new exploration targets generated by the extensive ground geophysics programs completed earlier this yearTORONTO, June 07, 2023 (GLOBE NEWSWIRE) — Angus Gold Inc. (TSX-V: GUS | OTC:...

Continue reading

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is Expected to Enter Phase 1 Clinical Development in Third Quarter 2023 CHATHAM, N.J, June 07, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from two oral presentations and one poster presentation at the 2023 American Transplant Congress (ATC) by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital. The data involve studies of Tonix’s TNX-1500 (Fc-modified anti-CD40L monoclonal antibody) in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Copies of the presentations are available...

Continue reading

Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California

GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and University of California, Davis (UC Davis), today announce an agreement to roll out proprietary Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) at medical or academic institutions within the University of California system. The partnership agreement sets out a staged approach through which Orgenesis will install and operate OMPULs™, enabling their proprietary point-of-care (“POCare”) Service Platform to manufacture therapeutics at hospitals throughout California, empowering onsite production for clinical trials like the cell and gene therapies in development...

Continue reading

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

Topline results from the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis are expected in Q4 2023 ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 SERENITY trial of VTX958 in plaque psoriasis. “I am very proud of our team’s execution as we mark another important milestone for Ventyx and for ulcerative colitis and plaque psoriasis patients,” said Dr. William Sandborn, President and Chief Medical...

Continue reading

Plug Supplies 8 MW of Hydrogen Fuel Cells to Energy Vault to Displace Diesel Generators in California Wine Country

Plug Fuel Cells Will Displace Diesel Generators to Power Microgrid During Wildfires and Other Emergencies in California Wine Country LATHAM, N.Y., June 07, 2023 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a leading provider of turnkey hydrogen solutions for the global green hydrogen economy, announced it will supply Energy Vault Holdings, Inc. with 8 MW (megawatts) of hydrogen fuel cell stationary power to deliver clean energy to the city of Calistoga, located in California Wine Country, during times of wildfires and other emergencies. This will be the largest planned hydrogen powered fuel cell installation in the United States. The California Public Utility Commission (CPUC) requires that state utility grid operators shut off power during severe weather to help prevent wildfires. Energy Vault has typically rented mobile...

Continue reading

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Study did not meet the primary endpoint Pamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. The study did not meet the primary endpoint of Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52 compared to baseline. Pamrevlumab was generally safe and well tolerated and the majority of treatment emergent adverse events were mild or moderate. FibroGen plans to present the complete results of the LELANTOS-1 study at an upcoming medical...

Continue reading

Reliance Steel & Aluminum Co. Announces Participation at the 2023 Wells Fargo Industrials Conference

SCOTTSDALE, Ariz., June 07, 2023 (GLOBE NEWSWIRE) — Reliance Steel & Aluminum Co. (NYSE: RS) announced today that Karla Lewis, Chief Executive Officer, and Steve Koch, Chief Operating Officer, will participate in the 2023 Wells Fargo Industrials Conference on Wednesday, June 14th at the InterContinental Chicago Magnificent Mile. Reliance is scheduled to present at 11:45 a.m. CT and will participate in meetings with investors throughout the day. The presentation will be webcast live over the Internet, hosted on the Investors section of the Company’s website at investor.rsac.com. In addition to the live webcast, a replay will be available on the Company’s website for 90 days following the event. About Reliance Steel & Aluminum Co. Founded in 1939, Reliance Steel & Aluminum Co. (NYSE: RS) is a leading global...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.